Pharmaceutical - Financial, Merck & Co

Filter

Current filters:

FinancialMerck & Co

Popular Filters

1 to 25 of 41 results

Merck strengthens commitment to Chinese growth market

Merck strengthens commitment to Chinese growth market

23-07-2014

Germany’s Merck KGaA, a leading company for high-tech products in the pharmaceutical and chemical sectors,…

ChinaFinancialMerckMerck KGaAPharmaceuticalProductionResearch

Merck KGaA takes currency hit in first quarter 2014

Merck KGaA takes currency hit in first quarter 2014

15-05-2014

German pharma and chemicals major Merck KGaA has reported first-quarter 2014 financial result, saying…

Business FinanceChemicalsEURFinancialMerckMerck KGaAPharmaceuticalSerono

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials

03-05-2014

US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

Merck & Co posts mixed 1st-qtr 2014 results

Merck & Co posts mixed 1st-qtr 2014 results

29-04-2014

US pharma giant Merck & Co today reported first-quarter 2014 adjusted diluted earnings per share (EPS)…

FinancialMerck & CoPharmaceutical

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

26-02-2014

US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

Merck & Co results disappoint, as the firm takes a hit from generics

Merck & Co results disappoint, as the firm takes a hit from generics

05-02-2014

Reporting fourth-quarter and full-year 2013 financial results yesterday, US pharma giant Merck & Co said…

FinancialMerck & CoPharmaceutical

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Forest spends $240 million for US rights to Saphris; streamlines operations

02-12-2013

US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

Merck & Co sales and earnings fall, but latter still beat expectations

Merck & Co sales and earnings fall, but latter still beat expectations

29-10-2013

US pharma giant Merck & Co posted third-quarter 2013 financial results, with declines in both sales and…

FinancialMerck & CoPharmaceutical

Merck & Co joins string of “restructurers,” cutting 8,500 jobs

Merck & Co joins string of “restructurers,” cutting 8,500 jobs

02-10-2013

US pharma giant Merck & Co is the latest of a flood of leading drugmakers to announce restructuring plans,…

FinancialManagementMerck & CoPharmaceuticalResearch

Aspen Pharma reports rise in profits from new product launches

11-09-2013

South Africa's leading drugmaker Aspen Pharmacare (APN: SJ) has released financial results which show…

ArixtraAspen PharmacareFinancialFraxiparineGlaxoSmithKlineMerck & CoPharmaceuticalRest of the World

Merck & Co records loss in 2nd quarter as Singulair drops 80%

30-07-2013

US pharma giant Merck & Co (NYSE: MRK) has released second quarter results showing that worldwide sales…

FinancialGardasilIsentressJanumetJanuviaMerck & CoNorth AmericaPharmaceuticalRemicadeSimponi ARIASingulairVytorinZetia

Merck & Co 1st-qtr sales down 9%, coming below analysts' expectations; lowers guidance

02-05-2013

US pharma giant Merck & Co (NYSE: MRK) posted first-quarter 2013 results, showing that worldwide sales…

FinancialMerck & CoPharmaceutical

Merck & Co provides C$4 million for Pan-Canadian life sciences research innovation sector

23-04-2013

Merck Canada, a unit of US pharma giant Merck & Co (NYSE: MRK) has announced that it is reinforcing its…

FinancialMerck & CoNorth AmericaPharmaceuticalResearch

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Merck & Co submits ragweed AIT BLA to the FDA

11-03-2013

US pharma giant Merck & Co (NYSE: MRK) has submitted a Biologics License Application (BLA) to the US…

ALK AbelloFinancialImmunologicalsMerck & CoNorth AmericaPharmaceuticalRegulation

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages

15-02-2013

US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

Merck & Co sales and earnings fall, hit by patent expiries, but beat expectations

04-02-2013

Shares of US pharma giant Merck & Co (NYSE: MRK) tracked 2.9% lower to $41.98 Friday morning, when the…

FinancialMerck & CoPharmaceutical

New Zealand considers listing Merck & Co's Bridion

30-01-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list the…

Asia-PacificBridionFinancialMerck & CoNeurologicalPharmaceuticalRegulation

1 to 25 of 41 results

Back to top